Answers are grounded in this paper and cite their sources.
The advent of acid-citrate-dextrose (ACD) storage solution effectively initiated 4°C whole blood storage and has provided the basis for many subsequent red blood cell (RBC) storage developments.1 Since early studies had shown poor RBC preservation in the presence of storage induced hemolysis, these studies included a 1% poststorage hemolysis goal. Later developments focused on the avoidance of the collection lesion and utilized osmotic fragility hemolysis measurements as one of the markers of stored RBC quality in the development of citrate-phosphate-dextrose (CPD).2 Ensuing developments focused on packed RBCs, which had the limitation that reduced RBC quality was observed if storage hematocrit (Hct) exceeded 70% and was associated with increased poststorage hemolysis. Since these RBC quality deficiencies were noted at the same time as the conversion to CPD-adenine, the newer storage solutions contained higher glucose levels to ensure adequate nutrient availability for satisfactory RBC recoveries at the end of 35 days of storage.3 At 35 days with a 75% storage Hct, CPDA-1 packed cell supernatant hemoglobin (Hb) levels averaged approximately 0.4% with CPDA-1–packed RBC posttransfusion recovery of 71%, which then supported product approval. The current generation of RBC additive solutions (ASs) was driven by the need to correct the poor CPD flow properties through the addition of saline-adenine-glucose (SAG) solutions. Hemolysis levels averaged 0.77%, although it was noted that posttransfusion recoveries were unaffected.4 Later it was shown that poststorage hemolysis levels in SAG-RBCs could be reduced by the addition of plasma or by reduction of white cell content. The effect of white blood cells (WBCs) could be reduced by enzyme inhibitors suggesting that it was intracellular enzymes that affected RBC membranes. Subsequent AS development included buffy coat (BC) depletion as a prerequisite, and formulations included mannitol (SAGM), an osmotic stabilizer, since the combination exhibited poststorage hemolysis comparable to whole blood.5 The concern about hemolysis was a principal goal of AS-1 development. This solution allowed the storage of nonleukoreduced RBCs for 42 days after high-efficiency plasma removal with poststorage hemolysis averaging approximately 0.27% (Adsol, Fenwal, Inc., Lake Zurich, IL).6 The addition of extra mannitol was essential for reduced hemolysis, since comparable non–mannitol (AS-3)-based additives were associated with hemolysis levels averaging 0.7 ± 0.56% compared to mannitol-based additives (0.38 ± 0.19%).7 The formulation of SAGM adopted for the US market contained a higher adenine load and comparable mannitol levels to that of SAGM but exhibited slightly greater 42-day poststorage hemolysis than AS-1 (AS-5, Optisol, Terumo, Inc., Elkton, MD).8 Later review of current US AS formulations (AS-1, AS-3, and AS-5) suggested that although RBC viability correlated reasonably with RBC ATP (r = ∼0.6) in standard RBC products, hemolysis correlated poorly (r = ∼0.4) with viability.9 It was the later development of high efficiency prestorage 3- to 5-log leukoreduction filters that enabled significant reductions in poststorage hemolysis from 0.54% to 0.18%. These studies showed a small (2%-3%) but significant improvement in RBC recoveries and that residual unfiltered WBC content correlated with RBC lactate production; in filtered units glucose consumption correlated with poststorage osmotic fragility, suggesting a membrane-based stress effect on RBC metabolism. RBC recoveries in filtered units correlated with hemolysis after 42 days of storage when the long-term membrane effect might be expected to be at its greatest.10 Other studies failed to show such a relationship. European-style additives (SAGM) in routine use have therefore included leukoreduction, initially through BC reduction using top-and-bottom bags11 and more recently with the addition of prestorage leukofiltration. In the United States, AS systems are used mostly with prestorage filtration.10, 12 The Australian family of additives (AS-3) included more adenine and citrate instead of mannitol, modified through the addition of high-efficiency prestorage leukofiltration (Leukotrap-RC system, Pall Corp., Roslyn, NY). In this issue of TRANSFUSION, Hess and the BEST team13 review the hemolysis quality outcome measures in AS-RBC over approximately 10 years of routine AS RBC manufacture and storage. This study includes a large enough sample size to offer insights into the effect of different solutions and some perspective on biologic variability in practice. These studies confirmed a significant effect of prestorage leukoreduction on poststorage hemolysis. In the largest comparison, the use of high-efficiency prestorage leukofiltration reduced hemolysis by approximately 50% from 0.34% in standard units to 0.16%, a reduction similar to that of earlier studies.10 It should be noted that the BC reduced/unfiltered group utilized AS-1, which contains approximately 1.7 × the amount of adenine of the earlier SAGM, although this fact would be unlikely to explain AS-1 and SAGM differences. The combination of filtration and BC leukoreduction was associated with a further improvement in poststorage hemolysis outcomes confirming that, even at low residual levels of WBCs, WBC content did affect hemolysis rates, as had been suggested earlier.10 These observations suggest a priority for the development of further improvements in filtration efficiency, since BC depletion reduces the mean RBC content by 24 mL or 13% of the original donation.14 The BEST group also looked at the effect of storage Hct on poststorage hemolysis and showed that while there was an effect, it was small at approximately 0.1%. Unit Hct levels have limited variability since these are affected by donor Hb levels, different separation centrifugation efficiencies, and the postseparation residual plasma volume. Since hemolysis might be affected by residual plasma content, or by the residual WBC content, either might affect the final Hct in a BC depletion system, and some effect of Hct on hemolysis is not surprising. In this respect it would be interesting to analyze the differential effect of mannitol and filtration efficiency since SAGM is most commonly applied to BC-depleted RBCs, and AS-3 is usually used with prestorage leukoreduction, which would affect residual WBC loads. The differences in hemolysis between SAGM and AS-1 were significant, confirming the dose-related effects of mannitol, which had been predicted when AS-1 was developed.6 In leukoreduced units, storage duration was associated with modest (approx. 0.06%) increases in hemolysis. Taken together these studies suggest that if only hemolysis was a consideration, high-efficiency leukoreduction and high mannitol content should be associated with lowest poststorage hemolysis. In practice prestorage leukoreduction eliminated the more significant differences between ASs that were observed with standard RBC products.6 Taken together only a small fraction, approximately 1:175 units, had greater than 1% hemolysis. The US Food and Drug Administration (FDA) previously required poststorage hemolysis levels of less than 0.5%, as well as RBC posttransfusion recoveries of more than 70% to support approval of a RBC product. These standards were discussed at the FDA Blood Products Advisory Committee in December 1982, at which time it was noted that the previous 0.5% hemolysis standard had hindered additive development, although there was little discussion that hemolysis at this level was cause for concern. Although no recommendations were made on either standard, subsequently the application of both standards changed in practice toward requiring 75% posttransfusion RBC recoveries and less than 1.0% for hemolysis at the end of the storage period. The later European standard of 0.8% added variance criteria to the standard, which is now included in the Council of Europe guide.15 However, in the late 1990s the standard was expanded to require that 95% of products tested meet the hemolysis standard 95% of the time, the 95/95 rule (J. Fratantoni, personal communication, 2009). When applied in practice, in a sample size of 60, at least 57 must have hemolysis of less than 1% for a high probability of less than 5% of failures. Based on the distribution of the data in the BEST study, where 98.4% exhibit a hemolysis success rate of less than 1%, as many as 1 in 60 (a recommended trial size) are expected to miss this standard. The difficulty is that, assuming Poisson distribution of the observed hemolysis values, more may fail. To achieve a 95% probability of success, a larger sample size will be necessary, or the mean study hemolysis level must approximate 0.35%. While a 60-unit study does not sound large, it represents a significant fraction of the available US RBC product licensing laboratory capacity for a single product approval study. As a consequence, new product development should be documented by in-vitro-only studies if the rate of development is to be sustained. An alternative would be the use of paired trials. These developments raise the question of the potential recipient effects of poststorage hemolysis at such low levels. Early studies had suggested that hemoglobinuria does not occur until plasma Hb levels exceed 100 mg/dL. Assuming 0.25% poststorage hemolysis, and a mean of 190 mL of RBCs/unit, a non-RBC Hb load of approximately 160 mg/unit would be infused. At normal haptoglobin levels, the physiologic Hb binding capacity is approximately 1 g of Hb/L of plasma, or that present in approximately 20 units of 42-day-old AS-RBCs. These quantities are compatible with a trauma study report, where free plasma Hb was not detected until 2 L of 12-day-old CPD whole blood had been transfused.16 Since recent reviews have suggested that dose-dependent symptoms may be observed after more than 2 g of cell free Hb has been administered, it would be uncommon that non-RBC Hb loads unbound to haptoglobin would reach symptomatic levels.17 Currently most RBCs are infused after shorter storage periods, and with few donations having high poststorage hemolysis, the direct risk from non-RBC Hb would appear to be low. In addition a number of studies has shown that it is the stroma rather than the free Hb of RBC hemolysates that is most strongly associated with coagulopathy symptoms.18 However, not all supernatant Hb is free Hb, but much is in microvesicles,19 which are shed by the RBCs during storage. The development of echinocytes is associated with changes in RBC volume and surface area, which occur with longer storage duration. The formation of microvesicles is reduced if blood is stored in polyvinyl chloride bags plasticized with lipid soluble plasticizers such as diethylhexyl phthalate or butyryl-trihexyl-citrate. In addition hemolysis may be reduced through the use of hypotonic storage media,20 although other studies have not shown this approach to be related to improved in vivo survival.21 An intriguing recent in vitro study has suggested that microvesicles may exert a transfusion-induced facilitation of thrombin effect after more than 21 days of AS-1 storage, as measured by thromboelastography.22 This association is of interest since a number of studies have suggested that less effective outcomes may follow transfusion with older units, although whether hemolysis is an effective predictor of such risk is unclear.23 Another potential recipient effect of free supernatant Hb could arise from nitric oxide (NO) binding to Hb and its ability to affect smooth muscle tone with an associated effect on peripheral vascular blood flow.24 Experimental studies have shown that cell-free Hb reduces NO tissue availability,25 and complex models have been developed to assess the role of Hb molecules as molecular scavengers.26 The relationship between intracellular NO, which is bound as S-nitrosothiol, and cell storage is complex and has been reviewed previously.27 Although a number of studies have suggested significant roles for plasma Hb in this activity, it is not clear how storage-compromised RBCs, microvesicular Hb, or free plasma Hb might interact to mediate an NO effect, to the point that a defined level of hemolysis should be viewed a surrogate safety marker and therefore an applicable regulatory standard. Certainly this might become an interesting area for study. The studies reported by Hess and the BEST collaborative offer an interesting insight into one of the biologic variables of blood storage, which has long been regarded as marker of RBC quality. The outcomes over wide population groups, and long periods of time, emphasize the consistency that has been made possible by the simultaneous application of additive solutions and prestorage leukoreduction. These quality control data of poststorage RBC hemolysis affirm a significant benefit of the combined effects of ASs and leukoreduction, which was not anticipated during the development of these storage media. From the hemolysis data, it would appear that the combination of BC depletion and filtration is no longer needed to minimize hemolysis. The combination of filtration (associated with approx. 6% RBC loss), discontinuance of BC depletion (avoidance of 13% loss), and improved RBC quality (approx. 3% gain) should make approximately 10% more Hb available to the recipient and retain the most reticulocyte-rich portion of the RBC content. The need for BC depletion should now be reassessed. Finally it may also be time to reconsider the hemolysis standard, since this approvability standard could limit future development, in key areas such as pathogen reduction, without conferring any improved safety. The author declares no conflict of interest.
No takes yet. Share an insight, caveat, or question.
Wm. Andrew Heaton (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: